Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 9, Issue 1, 2009, Pages 62-77

  Fuchs, Ota ^a,b   Provaznikova, Dana ^a,b   Marinov, Iuri ^a   Kuzelova, Katerina ^a   Spicka, Ivan ^c  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Apoptosis; Histone deacetylase inhibitors; Leukemia; Proteasome; Proteasome inhibitors

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; BORTEZOMIB; CARFILZOMIB; CASPASE 3; CASPASE 9; CYTARABINE; CYTOCHROME C; DOXORUBICIN; FR 23522; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; IDARUBICIN; IMMUNOSUPPRESSIVE AGENT; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PANOBINOSTAT; PR 171; PROTEASOME INHIBITOR; PROTEINASE INHIBITOR; REACTIVE NITROGEN SPECIES; ROMIDEPSIN; SALINOSPORAMIDE A; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VORINOSTAT; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; ENZYME INHIBITOR; HISTONE DEACETYLASE; LACTONE; OLIGOPEPTIDE; PYRAZINE DERIVATIVE; PYRROLE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CLINICAL TRIAL; DIARRHEA; DNA FRAGMENTATION; DNA SYNTHESIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME INACTIVATION; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; HUMAN; HYPERBILIRUBINEMIA; HYPOXIA; LEUKEMIA; LEUKEMIA CELL LINE; LYMPHOCYTOPENIA; LYMPHOMA; MITOCHONDRIAL PERMEABILITY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; OXIDATIVE STRESS; PERIPHERAL NEUROPATHY; PNEUMONIA; PROTEIN CLEAVAGE; RECOMMENDED DRUG DOSE; SIDE EFFECT; THROMBOCYTOPENIA; UBIQUITINATION; ANIMAL; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; PATHOPHYSIOLOGY; REVIEW; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; LACTONES; LEUKEMIA; OLIGOPEPTIDES; PROTEASE INHIBITORS; PYRAZINES; PYRROLES;

EID: 65549136174     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152909787581372     Document Type: Article

References (137)

1. Hershko, A.; Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem., 1998, 67, 425-479.
2. Pickart, C.M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem., 2001, 70, 503-533.
3. Glickman, M.H.; Ciechanover, A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev., 2002, 82, 373-428.
4. Pickart, C.M.; Cohen R.E. Proteasomes and their kin: proteases in the machine age. Nat. Rev. Mol. Cell Biol., 2004, 5, 177-187.
5. Hershko, A. Rev.: Nobel Lecture. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ., 2005, 12, 1191-1197.
6. Ciechanover, A. Intracellular protein degradation from a vague idea through the lysosome and the ubiquitin-proteasome system and on to human diseases and drug targeting: Nobel Lecture, December 8, 2004. Ann. N. Y. Acad. Sci., 2007, 1116, 1-28.
7. Rose, I. Rev.: Nobel Lecture. Ubiquitin at Fox Chase. Cell Death Differ., 2005, 12, 1162-1166.
8. Wilkinson, K.D. Ubiquitin: A Nobel protein. Cell, 2004, 119, 741-745.
9. Koegl, M.; Hoppe, T.; Schlenker, S.; Ulrich, H.D.; Mayer, T.U.; Jentsch, S. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell, 1999, 96, 635-644.
10. Staub, O.; Rotin, D. Role of ubiquitylation in cellular membrane transport. Physiol. Rev., 2006, 86, 669-707.
11. Savory, P.J.; Rivett, A.J. Leupeptin-binding site(s) in the mammalian multicatalytic proteinase complex. Biochem. J., 1993, 289, 45-48.
12. Vinitsky, A.; Cardozo, C.; Sepp-Lorenzino, L.; Michaud, C.; Orlowski, M. Inhibition of the proteolytic activity of the multicatalytic proteinase complex (proteasome) by substrate-related peptidyl aldehydes. J. Biol. Chem., 1994, 269, 29860-29866.
13. Imajoh-Ohmi, S.; Kawaguchi, T.; Sugiyama, S.; Tanaka, K.; Omura, S.; Kikuchi, H. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem. Biophys. Res. Commun., 1995, 217, 1070-1077.
14. Shinohara, K.; Tomioka, M.; Nakano, H.; Toné, S.; Ito, H.; Kawashima, S. Apoptosis induction resulting from proteasome inhibition. Biochem. J., 1996, 317, 385-388.
15. Delic, J.; Masdehors, P.; Omura, S.; Cosset, J.M.; Dumont, J.; Binet, J.L.; Magdelénat, H. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alphainitiated apoptosis. Br. J. Cancer., 1998, 77, 1103-1107.
16. Orlowski, R.Z.; Eswara, J.R.; Lafond-Walker, A.; Grever, M.R.; Orlowski, M.; Dang, C.V. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res., 1998, 58, 4342-4348.
17. Vinitsky, A.; Michaud, C.; Powers, J.C.; Orlowski, M. Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry, 1992, 31, 9421-9428.
18. Palombella, V.J.; Rando, O.J.; Goldberg, A.L.; Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NFkappa B1 precursor protein and the activation of NF-kappa B. Cell, 1994, 78, 773-785.
19. Rock K.L.; Gramm, C.; Rothstein, L.; Clark, K.; Stein, R.; Dick, L.; Hwang, D.; Goldberg, A.L. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell, 1994, 78, 761-771.
20. Adams, J.; Behnke, M.; Chen, S.; Cruickshank, A.A.; Dick, L.R.; Grenier, L.; Klunder, J.M.; Ma, Y.T.; Plamondon, L.; Stein, R.L. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett., 1998, 8, 333-338.
21. Adams, J.; Kauffman, M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest., 2004, 22, 304-311.
22. Adams, J. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer., 2004, 4, 349-360.
23. Kane, R.C.; Bross, P.F.; Farrell, A.T.; Pazdur, R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist., 2003, 8, 508-551.
24. Kane, R.C.; Farrell, A.T.; Sridhara, R.; Pazdur, R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin. Cancer Res., 2006, 12, 2955-2960.
25. Richardson, P.G.; Sonneveld, P.; Schuster, M.W.; Irwin, D.; Stadtmauer, E.A.; Facon, T.; Harousseau, J.L.; Ben-Yehuda, D.; Lonial, S.; San Miguel, J.F.; Cavenagh, J.D.; Anderson, K.C. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br. J. Haematol., 2007, 137, 429-435.
26. Mitsiades, C.S.; Hayden, P.J.; Anderson, K.C.; Richardson, P.G. From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract. Res. Clin. Haematol., 2007, 20, 797-816.
27. Chauhan, D.; Hideshima, T.; Anderson, K.C. Targeting proteasomes as therapy in multiple myeloma. Adv. Exp. Med. Biol., 2008, 615, 251-260.
28. Goy, A.; Younes, A.; McLaughlin, P.; Pro, B.; Romaguera, J.E.; Hagemeister, F.; Fayad, L.; Dang, N.H.; Samaniego, F.; Wang, M.; Broglio, K.; Samuels, B.; Gilles, F.; Sarris, A.H.; Hart, S.; Trehu, E.; Schenkein, D.; Cabanillas, F.; Rodriguez, A.M. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J. Clin. Oncol., 2005, 23, 667-675.
29. O'Connor, O.A.; Wright, J.; Moskowitz, C.; Muzzy, J.; MacGregor-Cortelli, B.; Stubblefield, M.; Straus, D.; Portlock, C.; Hamlin, P.; Choi, E.; Dumetrescu, O.; Esseltine, D.; Trehu, E.; Adams, J.; Schenkein, D.; Zelenetz, A.D. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J. Clin. Oncol., 2005, 23, 676-684.
30. Suh, K.S.; Gay, A. Bortezomib in mantle cell lymphoma. Future Oncol., 2008, 4, 149-168.
31. Hideshima, T.; Chauhan, D.; Richardson, P.; Mitsiades, C.; Mitsiades, N.; Hayashi, T.; Munshi, N.; Dang, L.; Castro, A.; Palombella, V.; Adams, J.; Anderson, K.C. NF-kappa B as a therapeutic target in multiple myeloma. J. Biol. Chem., 2002, 277, 16639-16647.
32. Hideshima, T.; Richardson, P.; Chauhan, D.; Palombella, V.J.; Elliott, P.J.; Adams, J.; Anderson, K.C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res., 2001, 61, 3071-3076.
33. Roccaro, A.M.; Vacca, A.; Ribatti, D. Bortezomib in the treatment of cancer. Recent Patents Anticancer Drug Discov., 2006, 1, 397-403.
34. Roccaro, A.M.; Hideshima, T.; Raje, N.; Kumar, S.; Ishitsuka, K.; Yasui, H.; Shiraishi, N.; Ribatti, D.; Nico, B.; Vacca, A.; Dammacco, F.; Richardson, P.G.; Anderson, K.C. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res., 2006, 66, 184-191.
35. Hideshima, T.; Bradner, J.E.; Wong, J.; Chauhan, D.; Richardson, P.; Schreiber, S.L.; Anderson, K.C. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl. Acad. Sci. USA, 2005, 102, 8567-8572.
36. Nawrocki, S.T.; Carew, J.S.; Dunner, K., Jr., Boise, L.H.; Chiao, P.J.; Huang, P.; Abbruzzese, J.L.; McConkey, D.J. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res., 2005, 65, 11510-11519.
37. Nawrocki, S.T.; Carew, J.S.; Pino, M.S.; Highshaw, R.A.; Dunner, K., Jr, Huang, P.; Abbruzzese, J.L.; McConkey, D.J. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stressmediated apoptosis. Cancer Res., 2005, 65, 11658-11666.
38. Lee, A.H.; Iwakoshi, N.N.; Anderson, K.C.; Glimcher, L.H. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc. Natl. Acad. Sci. USA, 2003, 100, 9946-9951.
39. Obeng, E.A.; Carlson, L.M.; Gutman, D.M.; Harrington, W.J., Jr., Lee, K.P.; Boise, H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood, 2006, 107, 4907-4916.
40. Orlowski, R.Y.; Baldwin, A.S. NF-κB as a therapeutic target in cancer.Trends Mol. Med., 2002, 8, 385-389.
41. Luo, J.L.; Maeda, S.; Hsu, L.C.; Yagita, H.; Karin, M. Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell, 2004, 6, 297-305.
42. Pikarsky, E.; Porat, R.M.; Stein, I.; Abramovitch, R.; Amit, S.; Kasem, S.; Gutkovich-Pyest, E.; Urieli-Shoval, S.; Galun, E.; Ben-Neriah, Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature, 2004, 431, 461-466.
43. Wang, C.Y.; Mayo, M.W.; Baldwin, A.S., Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NFkappaB. Science, 1996, 274, 784-787.
44. Wang, C.Y.; Cusack, J.C., Jr., Liu, R.; Baldwin, A.S., Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med., 1999, 5, 412-417.
45. Cusack, J.C., Jr., Liu, R.; Houston, M.; Abendroth, K.; Elliott, P.J.; Adams, J.; Baldwin, A.S., Jr. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res., 2001, 61, 3535-3540.
46. Cusack, J.C.; Liu, R.; Baldwin, A.S. NF- kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF- kappa B. Drug Resist. Updat., 1999, 2, 271-273.
47. Russo, S.M.; Tepper, J.E.; Baldwin, A.S., Jr., Liu, R.; Adams, J.; Elliott, P.; Cusack, J.C., Jr. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int. J. Radiat. Oncol. Biol. Phys., 2001, 50, 183-193.
48. Liu, S.; Liu, Z.; Xie, Z.; Pang, J.; Yu, J.; Lehmann, E.; Huynh, L.; Vukosavljevic, T.; Takei, M.; Klisovic, R.B.; Baiocchi, R.A.; Blum, W.; Porcu, P.; Garzon, R.; Byrd, J.C.; Perrotti, D.; Caligiuri, M.A.; Chan, K.K.; Wu, L.-C.; Marcucci, G. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/ NF-κB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood, 2008, 111, 2364-2373.
49. Herman, J.G.; Baylin, S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Eng. J. Med., 2003, 349, 2042-2054.
50. Plass, C.; Oakes, C.; Blum, W.; Marcucci, G. Epigenetics in acute myeloid leukemia. Semin. Oncol., 2008, 35, 378-387.
51. Garcia-Manero, G. Demethylating agents in myeloid malignancies. Curr. Opin. Oncol. 2008, 20, 705-710.
52. Ishii, Y.; Pirkmaier, A.; Alvarez, J.V.; Frank, D.A.; Keselman, I.; Logothetis, D.; Mandeli, J.; O'Connell, M.J.; Waxman, S.; Germain, D. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. J. Natl. Cancer Inst., 2006, 98, 1238-1247.
53. Keats, J.J.; Fonseca, R.; Chesi, M.; Schop, R.; Baker, A.; Chng, W.J.; Van Wier, S.; Tiedemann, R.; Shi, C.X.; Sebag, M.; Braggio, E.; Henry, T.; Zhu, Y.X.; Fogle, H.; Price-Troska, T.; Ahmann, G.; Mancini, C.; Brents, L.A.; Kumar, S.; Greipp, P.; Dispenzieri, A.; Bryant, B.; Mulligan, G.; Bruhn, L.; Barrett, M.; Valdez, R.; Trent, J.; Stewart, A.K.; Carpten, J.; Bergsagel, P.L. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell, 2007, 12, 131-144.
54. Dolcet, X.; Llobet, D.; Encinas, M.; Pallares, J.; Cabero, A.; Schoenenberger, J.A.; Comella, J.X.; Matias-Guiu, X. Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants. J. Biol. Chem., 2006, 281, 22118-22130.
55. Rumpold, H.; Salvador, C.; Wolf, A.M.; Tilg, H.; Gastl, G.; Wolf, D. Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem. Biophys. Res. Commun., 2007, 361, 549-554.
56. Richardson, P.G.; Briemberg, H.; Jagannath, S.; Wen, P.Y.; Barlogie, B.; Berenson, J.; Singhal, S.; Siegel, D.S.; Irwin, D.; Schuster, M.; Srkalovic, G.; Alexanian, R.; Rajkumar, S.V.; Limentani, S.; Alsina, M.; Orlowski, R.Z.; Najarian, K.; Esseltine, D.; Anderson, K.C.; Amato, A.A. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J. Clin. Oncol., 2006, 24, 3113-3120.
57. Lonial, S.; Waller, E.K.; Richardson, P.G.; Jagannath, S.; Orlowski, R.Z.; Giver, C.R.; Jaye, D.L.; Francis, D.; Giusti, S.; Torre, C.; Barlogie, B.; Berenson, J.R.; Singhal, S.; Schenkein, D.P.; Esseltine, D.L.; Anderson, J.; Xiao, H.; Heffner, L.T.; Anderson, K.C. SUMMIT/CREST Investigators. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood, 2005, 106, 3777-3784.
58. Badros, A.; Goloubeva, O.; Dalal, J.S.; Can, I.; Thompson, J.; Rapoport, A.P.; Heyman, M.; Akpek, G.; Fenton, R.G. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer, 2007, 110, 1042-1049.
59. San Miguel, J.; Bladé, J.; Boccadoro, M.; Cavenagh, J.; Glasmacher, A.; Jagannath, S.; Lonial, S.; Orlowski, R.Z.; Sonneveld, P.; Ludwig, H. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist, 2006, 11, 51-61.
60. Feling, R.H.; Buchanan, G.O.; Mincer, T.J.; Kauffman, C.A.; Jensen, P.R.; Fenical, W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew. Chem. Int. Ed. Engl., 2003, 42, 355-357.
61. Macherla, V.R.; Mitchell, S.S.; Manam, R.R.; Reed, K.A.; Chao, T.H.; Nicholson, B.; Deyanat-Yazdi, G.; Mai, B.; Jensen, P.R.; Fenical, W.F.; Neuteboom, S.T.; Lam, K.S.; Palladino, M.A.; Potts, B.C. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J. Med. Chem., 2005, 48, 3684-3687.
62. Chauhan, D.; Catley, L.; Li, G.; Podar, K.; Hideshima, T.; Velankar, M.; Mitsiades, C.; Mitsiades, N.; Yasui, H.; Letai, A.; Ovaa, H.; Berkers, C.; Nicholson, B.; Chao, T.H.; Neuteboom, S.T.; Richardson, P.; Palladino, M.A.; Anderson, K.C. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell, 2005, 8, 407-419.
63. Chauhan, D.; Hideshima T.; Anderson K.C. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br. J. Cancer, 2006, 95, 961-965.
64. Williamson, M.J.; Blank, J.L.; Bruzzese, F.J.; Cao, Y.; Daniels, J.S.; Dick, L.R.; Labutti, J.; Mazzola, A.M.; Patil, A.D.; Reimer, C.L.; Solomon, M.S.; Stirling, M.; Tian, Y.; Tsu, C.A.; Weatherhead, G.S.; Zhang, J.X.; Rolfe, M. Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib. Mol. Cancer Ther., 2006, 5, 3052-3061.
65. Miller, C.P.; Ban, K.; Dujka, M.E.; McConkey, D.J.; Munsell, M.; Palladino, M.; Chandra, J. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood, 2007, 110, 267-277.
66. Chauhan, D.; Singh, A.; Brahmandam, M.; Podar, K.; Hideshima, T.; Richardson, P.; Munshi, N.; Palladino, M.A.; Anderson, K.C. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood, 2008, 111, 1654-1664.
67. Demo, S.D.; Kirk, C.J.; Aujay, M.A.; Buchholz, T.J.; Dajee, M.; Ho, M.N.; Jiang, J.; Laidig, G.J.; Lewis, E.R.; Parlati, F.; Shenk, K.D.; Smyth, M.S.; Sun, C.M.; Vallone, M.K.; Woo, T.M.; Molineaux, C.J.; Bennett, M.K. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res., 2007, 67, 6383-6391.
68. Stapnes, C.; Døskeland, A.P.; Hatfield, K.; Ersvaer, E.; Ryningen, A.; Lorens J.B.; Gjertsen, B.T.; Bruserud, O. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br. J. Haematol., 2007, 136 814-828.
69. Kuhn, D.J.; Chen, Q.; Voorhees, P.M.; Strader, J.S.; Shenk, K.D.; Sun, C.M.; Demo, S.D.; Bennett, M.K.; van Leeuwen, F.W.; Chanan-Khan, A.A.; Orlowski, R.Z. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood, 2007, 110, 3281-3290.
70. Orlowski, R.Z.; Kuhn, D.J. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin. Cancer Res., 2008, 14, 1649-1657.
71. Ahn, K.S.; Sethi, G.; Chao, T.H.; Neuteboom, S.T.; Chaturvedi, M.M.; Palladino, M.A.; Younes, A.; Aggarwal, B.B. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NFkappaB regulated gene products. Blood, 2007, 110, 2286-2295.
72. Ruiz, S.; Krupnik, Y.; Keating, M.; Chandra, J.; Palladino, M.; McConkey, D. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol. Cancer Ther., 2006, 5, 1836-1843.
73. Cusack, J.C., Jr., Liu, R.; Xia, L.; Chao, T.H.; Pien, C.; Niu, W.; Palombella, V.J.; Neuteboom, S.T.; Palladino, M.A. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin. Cancer Res., 2006, 12, 6758-6764.
74. Xu, W.S.; Parmigiani, R.B.; Marks, P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene, 2007, 26, 5541-5552.
75. Mack, G.S. Epigenetic cancer therapy makes headway. J. Natl. Cancer Inst., 2006, 1443-1444.
76. Petrella, A.; D'Acunto, C.W.; Rodriquez, M.; Festa, M.; Tosco, A.; Bruno, I.; Terracciano, S.; Taddei, M.; Paloma, L.G.; Parente, L. Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of annexin A1. Eur. J. Cancer, 2008, 44, 740-749.
77. Garcia-Manero, G.; Assouline, S.; Cortes, J.; Estrov, Z.; Kantarjian, H.; Yang, H.; Newsome, W.M.; Miller, W.H., Jr., Rousseau, C.; Kalita, A.; Bonfils, C.; Dubay, M.; Patterson, T.A.; Li, Z.; Besterman, J.M.; Reid, G.; Laille, E.; Martell, R.E.; Minden, M. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood, 2008, 112, 981-989.
78. Minucci, S.; Nervi, C.; Lo Coco, F.; Pelicci, P.G. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene, 2001, 20, 3110-3115.
79. Bradbury, C.A.; Khanim, F.L.; Hayden, R.; Bunce, C.M.; White, D.A.; Drayson, M.T.; Craddock, C.; Turner, B.M. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia, 2005, 19, 1751-1759.
80. Glozak, M.A.; Seto, E. Histone deacetylases and cancer. Oncogene, 2007, 26, 5420-5432.
81. Yang, X.-J.; Seto, E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene, 2007, 26, 5310-5318.
82. Rasheed, W.K.; Johnstone, R.W.; Prince, H.M. Histone deacetylase inhibitors in cancer therapy. Expert Opin. Investig. Drugs, 2007, 16, 659-678.
83. Dokmanovic, M.; Clarke, C.; Marks, P.A. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res., 2007, 5, 981-989.
84. Marks, P.A.; Breslow, R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol., 2007, 25, 84-90.
85. Glaser, K.B. HDAC inhibitors: clinical update and mechanismbased potential. Biochem. Pharmacol., 2007, 74, 659-671.
86. Ocker, M.; Schneider-Stock, R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int. J. Biochem. Cell Biol., 2007, 39, 1367-1374.
87. Im, J.Y.; Park, H.; Kang, K.W.; Choi, W.S.; Kim, H.S. Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and-negative human breast cancer cells. Chem. Biol. Interact., 2008, 172, 235-244.
88. Shin, H.J.; Baek, K.H.; Jeon, A.H.; Kim, S.J.; Jang, K.L.; Sung, Y.C.; Kim, C.M.; Lee, C.W. Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation. Oncogene, 2003, 22, 3853-3858.
89. Dowling, M.; Voong, K.R.; Kim, M.; Keutmann, M.K.; Harris, E.; Kao, G.D. Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biol. Ther., 2005, 4, 197-206.
90. Ruefli, A.A.; Ausserlechner, M.J.; Bernhard, D.; Sutton, V.R.; Tainton, K.M.; Kofler, R.; Smyth, M.J.; Johnstone, R.W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci USA, 2001, 98, 10833-10838.
91. Henderson, C.; Mizzau, M.; Paroni, G.; Maestro, R.; Schneider, C.; Brancolini, C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J. Biol. Chem., 2003, 278, 12579-12589.
92. Luo, X.; Budihardjo, I.; Zou, H.; Slaughter, C.; Wang, X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 1998, 94, 481-490.
93. Li, H.; Zhu, H.; Xu, C.J.; Yuan, J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell, 1998, 94, 491-501.
94. Rosato, R.R.; Almenara, J.A.; Dai, Y.; Grant, S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther., 2003, 2, 1273-1284.
95. Kim, H.R.; Kim, E.J.;Yang, S.H.; Jeong, E.T.; Park, C.; Lee, J.H.; Youn, M.J.; So, H.S.; Park, R. Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptormediated and mitochondrial pathway? Exp. Mol. Med., 2006, 38, 616-624.
96. Gillenwater, A.M.; Zhong, M.; Lotan, R. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol. Cancer Ther., 2007, 6, 2967-2975.
97. Dai, Y.; Rahmani, M.; Dent, P.; Grant, S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NFkappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol. Cell Biol., 2005, 25, 5429-5444.
98. Ling, Y.-H.; Liebes, L.; Ng, B.; Buckley, M.; Elliott, P.J.; Adams, J.; Jiang, J.-D.; Muggia, F.M.; Perez-Soler, R. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol. Cancer Ther., 2002, 1, 841-849.
99. Pei, X.-Y.; Dai, Y.; Grant, S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin. Cancer Res., 2004, 10, 3839-3852.
100. Nawrocki, S.T.; Carew, J.S.; Pino, M.S.; Highshaw, R.A.; Andtbacka, R.H.; Dunner, K., Jr., Pal. A.; Bornmann, W.G.; Chiao, P.J.; Huang, P.; Xiong, H.; Abbruzzese, J.L.; McConkey, D.J. Aggresome disruption: a novel strategy to enhance bortezomibinduced apoptosis in pancreatic cancer cells. Cancer Res., 2006, 66, 3773-3781.
101. Hideshima, T.; Bradner, J.E.; Wong, J.; Chauhan, D.; Richardson, P.; Schreiber, S.L.; Anderson, K.C. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl. Acad. Sci. USA, 2005, 102, 8567-8572.
102. Cortes, J.; Thomas, D.; Koller, C.; Giles, F.; Estey, E.; Faderl, S.; Garcia-Manero, G.; McConkey, D.; Ruiz, S.L.; Guerciolini, R.; Wright, J.; Kantarjian, H. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin. Cancer Res., 2004, 10, 3371-3376.
103. Orlowski, R.Z.; Voorhees, P.M.; Garcia, R.A.; Hall, M.D.; Kudrik, F.J.; Allred, T.; Johri, A.R.; Jones, P.E.; Ivanova, A.; Van Deventer, H.W.; Gabriel, D.A.; Shea, T.C.; Mitchell, B.S.; Adams, J.; Esseltine, D.L.; Trehu, E.G.; Green, M.; Lehman, M.J.; Natoli, S.; Collins, J.M.; Lindley, C.M.; Dees, E.C. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood, 2005, 105, 3058-3065.
104. Attar, E.C.; De Angelo, D.J.; Supko, J.G.; D'Amato, F.; Zahrieh, D.; Sirulnik, A.; Wadleigh, M.; Ballen, K.K.; McAfee, S.; Miller, K.B.; Levine, J.; Galinsky, I.; Trehu, E.G.; Schenkein, D.; Neuberg, D.; Stone, R.M.; Amrein, P.C. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin. Cancer Res., 2008, 14, 1446-1454.
105. Suárez, L.; Vidriales, M.B.; García-Laraña, J.; Sanz, G.; Moreno, M.J.; López, A.; Barrena, S.; Martínez, R.; Tormo, M.; Palomera, L.; Lavilla, E.; López-Berges, M.C.; de Santiago, M.; de Equiza, M.E.; Miguel, J.F.; Orfao, A. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes. Clin. Cancer Res., 2004, 10, 7599-7606.
106. Suárez, L.; Vidriales, M.B.; Moreno, M.J.; López, A.; García-Laraña, J.; Pérez-López, C.; Tormo, M.; Lavilla, E.; López-Berges, M.C.; de Santiago, M.; San Miguel, J.F.; Orfao, A. PETHEMA Cooperative Group. Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells. Haematologica, 2005, 90, 54-59.
107. Colado, E.; Alvarez-Fernández, S.; Maiso, P.; Martín-Sánchez, J.; Vidriales, M.B.; Garayoa, M.; Ocio, E.M.; Montero, J.C.; Pandiella, A.; San Miguel, J.F. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. Haematologica, 2008, 93, 57-66.
108. Gil, L.; Styczynski, J.; Dytfeld, D.; Debski, R.; Kazmierczak, M.; Kolodziej, B.; Rafinska, B.; Kubicka, M.; Nowicki, A.; Komarnicki, M.; Wysocki, M. Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia. Anticancer Res., 2007, 27, 4021-4025.
109. Riccioni, R.; Senese, M.; Diverio, D.; Riti, V.; Buffolino, S.; Mariani, G.; Boe, A.; Cedrone M.; Lo-Coco, F.; Foa, R.; Peschle, C.; Testa, U. M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis. Br. J. Haematol., 2007, 139, 194-205.
110. Minderman, H.; Zhou, Y.; O'Loughlin, K.L.; Baer, M.R. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemother. Pharmacol., 2007, 60, 245-255.
111. Stapnes, C.; Ryningen, A.; Hatfield, K.; Øyan, A.M.; Eide, G.E.; Corbascio, M.; Kalland, K.H.; Gjertsen, B.T.; Bruserud, Ø. Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors. Int. J. Oncol., 2007, 31, 1529-1538.
112. Ryningen, A.; Bruserud, Ø. Epigenetic targeting in acute myeloid leukemia: use of flow cytometry in monitoring therapeutic effects. Curr. Pharm. Biotechnol., 2007, 8, 401-411.
113. Ryningen, A.; Stapnes, C.; Bruserud, Ø. Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting. Leuk. Res., 2007, 31, 1303-1313.
114. Sutheesophon, K.; Kobayashi, Y.; Takatoku, M.A.; Ozawa, K.; Kano, Y.; Ishii, H.; Furukawa, Y. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib. Acta Haematol., 2006, 115, 78-90.
115. Conticello, C.; Adamo, L.; Vicari, L.; Giuffrida R.; Iannolo, G.; Anastasi, G.; Caruso, L.; Moschetti, G.; Cupri, A.; Palumbo, G.A.; Gulisano, M.; De Maria, R.; Giustolisi, R.; Di Raimondo, F. Antitumor activity of bortezomib alone and in combination with Trail in human acute myeloid leukemia. Acta Haematol., 2008, 120, 19-30.
116. Fuchs, O.; Provaznikova, D.; Marinov, I.; Kuzelova, K.; Spicka, I. The proteasome inhibitor bortezomib as better inductor of apoptosis than transforming growth factor beta in human acute myeloid cell lines. FEBS J., 2008, 275(Suppl. 1), 305, Abstract PP7A-24.
117. Gatto, S.; Scappini, B.; Pham, L.; Onida, F.; Milella, M.; Ball, G.; Ricci, C.; Divoky, V.; Verstovsek, S.; Kantarjian, H.M.; Keating, M.J.; Cortes-Franco, J.E.; Beran, M. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica, 2003, 88, 853-863.
118. Yu, C.; Rahmani, M.; Conrad, D.; Subler, M.; Dent, P.; Grant, S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood, 2003, 102, 3765-3774.
119. Dai, Y.; Rahmani, M.; Pei, X.Y.; Dent, P.; Grant, S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/ Abl-dependent and -independent mechanisms. Blood, 2004, 104, 509-518.
120. Pahler, J.C.; Ruiz, S.; Niemer, I.; Calvert, L.R.; Andreeff, M.; Keating, M.; Faderl, S.; McConkey, D.J. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin. Cancer Res., 2003, 9, 4570-4577.
121. Kelley,T.W.; Alkan, S.; Srkalovic, G.; Hsi, E.D. Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. Leuk Res., 2004, 28, 845-850.
122. Duechler, M.; Linke, A.; Cebula, B.; Shehata, M.; Schwarzmeier, J.D.; Robak, T.; Smolewski, P. In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. Eur. J. Haematol., 2005, 74, 407-417.
123. Kabore, A.F.; Sun, J.; Hu, X.; McCrea, K.; Johnston, J.B.; Gibson, S.B. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis, 2006, 11, 1175-1193.
124. Ruiz, S.; Krupnik, Y.; Keating, M.; Chandra, J.; Palladino, M.; McConkey, D. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol. Cancer Ther., 2006, 5, 1836-1843.
125. Dai, Y.; Chen, S.; Kramer, L.B.; Funk, V.L.; Dent, P.; Grant, S. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin Cancer Res., 2008, 14, 549-558.
126. Tan, C.; Waldmann, T.A. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res., 2002, 62, 1083-1086.
127. Satou, Y.; Nosaka, K.; Koya, Y.; Yasunaga, J.I.; Toyokuni, S.; Matsuoka, M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia, 2004, 18, 1357-1363.
128. Nasr, R.; El-Sabban, M.E.; Karam, J.A.; Dbaibo, G.; Kfoury, Y.; Arnulf, B.; Lepelletier, Y.; Bex, F.; de Thé, H.; Hermine, O.; Bazarbachi, A. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene, 2005, 24, 419-430.
129. Hamamura, R.S.; Ohyashiki, J.H.; Kurashina, R.; Kobayashi, C.; Zhang, Y.; Takaku, T.; Ohyashiki, K. Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells. Br. J. Cancer, 2007, 97, 1099-1105.
130. Ozpuyan, F.; Meyer, P.; Ni, H.; Al-Masri, H.; Alkan, S. Bortezomib induces apoptosis in T-cell prolymphocytic leukemia (TPLL). Leuk. Lymphoma, 2007, 48, 2247-2250.
131. Ishitsuka, K.; Tamura, K. Treatment of adult T-cell leukemia/lymphoma: past, present, and future. Eur. J. Haematol., 2008, 80, 185-196.
132. Kraus, M.; Ruckrich, T.; Reich, M.; Gogel, J.; Beck, A.; Kammer, W.; Berkers, C.R.; Burg, D.; Overkleeft, H.; Ovaa, H.; Driessen, C. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia, 2007, 21, 84-92.
133. Oerlemans, R.; Franke, N.E.; Assaraf, Y.G.; Cloos, J.; van Zantwijk, I.; Berkers, C.R.; Scheffer, G.L.; Debipersad, K.; Vojtekova, K.; Lemos, C.; van der Heijden, J.W.; Ylstra, B.; Peters, G.J.; Kaspers, G.L.;
134. Vink, J.; Cloos, J.; Kaspers, G.J. Proteasome inhibition as novel treatment strategy in leukaemia. Br. J. Haematol., 2006, 134, 253-262.
135. McCloskey, S.M.; McMullin, M.F.; Walker, B.; Irvine, A.E. The therapeutic potential of the proteasome in leukaemia. Hematol. Oncol., 2008, 26, 73-81.
136. Sun, K.; Welniak, L.A.; Panoskaltsis-Mortari, A.; O'Shaughnessy, M.J.; Liu, H.; Barao, I.; Riordan, W.; Sitcheran, R.; Wysocki, C.; Serody, J.S.; Blazar, B.R.; Sayers, T.J.; Murphy, W.J. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc. Natl. Acad. Sci. USA, 2004, 101, 8120-8125.
137. Sun, K.; Wilkins, D.E.; Anver, M.R.; Sayers, T.J.; Panoskaltsis-Mortari, A.; Blazar, B.R.; Welniak, L.A.; Murphy, W.J. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood, 2005, 106, 3293-3299.